Summary:
- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients Interim Assessment Expected in Mid-2021 and Completion of Enrollment by Year-End 2021Protocol Submitted to FDA for Pharmacology Clinical Study with Data Expected in Second Half 2021YAVNE, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on its Escha...
YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it will participate in the forthcoming LifeSci Partners 10th Annual Corporate Access Event and the H.C. Wainwright BioConnect 2021 Conference. Both conferences will take place virtually. LifeSci Advisors Corporate Access Event (January 6-8 and 11-14) Management ...
Data to be Published in a Peer-Reviewed Journal in First Half 2021YAVNE, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the successful completion of a pre-clinical study designed to evaluate the debridement efficacy of EscharEx®, a novel bromelain-based enzymatic debridement agent, in a porcine hard-to-heal wound model, a...
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14) * Acceleron Pharma Inc (NASDAQ: XLRN) (announced orphan drug designation for sotatercept in pulmonary arterial hypertension) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Affimed NV (NASDAQ: AFMD) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) - announced a deal to be bought by AstraZeneca plc (NASDAQ: AZN) for $39 billion * Agios Pharmaceutic...
YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to ma...
If you want to know who really controls MediWound Ltd. (NASDAQ:MDWD), then you'll have to look at the makeup of its...
MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 2.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?